Changing the world around us
Our Global Vision & Goals
To improve clinical outcomes for neonates and children with serious bacterial infections through their prevention or optimal treatment.
Our interests are in optimal antimicrobial prescribing and includes determining the best drug, dose, duration, and formulation to the optimal indication to improve clinical outcomes.
Professor Mike Sharland and Dr Julia Bielicki are leading experts globally in antimicrobial prescribing, resistance, and healthcare-associated infections in neonates and children. The AMR team research interests are in optimal antimicrobial prescribing and includes determining the best drug, dose, duration, and formulation to the optimal indication to improve clinical outcomes, while minimising drug toxicity, costs, the selection of resistance, and increasing safety. Another primary interest is in post-marketing surveillance following drug licensing, and long-term surveillance.
The CNPI AMR team work in close collaboration with the Global Antibiotic Research and Development Partnership (GARDP) and the Penta Foundation, a global Paediatric Infectious Diseases research network; the team have collaborated with many global partners to address and combat the emerging threat of AMR, particularly in neonates and children.
Conducting major observational studies and surveys on antibiotic use globally in the ARPEC and GARPEC projects has supported trial planning and hypothesis generation, providing evidence base for conducting global antibiotic interventional clinical trials. This has included clinical trials to determine the optimal choice of drug, dose, duration and delivery to manage hospitalized children with severe pneumonia, including PediCAP.